Skip to main
COYA

COYA Stock Forecast & Price Target

COYA Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Coya Therapeutics is a clinical-stage biotechnology company with key programs focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases. Their recent publication showcasing the link between biomarkers and disease progression and survival in Amyotrophic Lateral Sclerosis (ALS) provides strong validation for their approach and supports the ongoing randomized ALSTARS trial. With updates planned for their lead asset COYA 302 in ALS and FTD, alongside clinical milestones and enrolling trials, Coya appears to be progressing towards a solid clinical development story that could de-risk the lead asset.

Bears say

Coya Therapeutics is facing several key risks, including clinical and regulatory risk, partnership risk, financial risk, commercial risk, and legal and intellectual property risk. While the recent publication in Brain Communications strengthens the company's scientific thesis and adds validation to their platform, it does not have a significant impact on near-term financial estimates. However, with milestones in clinical trials and sales, the company has the potential to grow in the future, but these risks should be carefully considered. Overall, the company's current outlook is negative due to the high level of risk involved and the lack of near-term financial impact from recent developments.

COYA has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Coya Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Coya Therapeutics Inc (COYA) Forecast

Analysts have given COYA a Strong Buy based on their latest research and market trends.

According to 5 analysts, COYA has a Strong Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Coya Therapeutics Inc (COYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.